బయోకెమిస్ట్రీ & ఫార్మకాలజీ: ఓపెన్ యాక్సెస్
అందరికి ప్రవేశం

నైరూప్య

Iguratimod Synergizes with Methotrexate to Exert Anti-Inflammatory and Bone-Protective Effect and Block the Progression of Collagen-Induced Arthritis in Mices

Qiang Xu

Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic synovial inflammation and disability.
The most widely used Disease-Modifying Antirheumatic Drug (DMARD) is methotrexate and it continues to be the gold
standard. However, the use of high-dose methotrexate is associated with severe adverse effects. Iguratimod, which is
currently used in clinics in China and Japan, is a novel oral DMARD for the treatment of RA. In this study, the effect
of combination of methotrexate and iguratimod on murine Collagen-Induced Arthritis (CIA) and its mechanism was
determined. Oral administration of iguratimod (3 mg/kg, 10 mg/kg) combined with methotrexate (1 mg/kg) potently
blocked CIA development and delayed its progression, which was stronger than iguratimod or methotrexate used alone.
Furthermore, infiltration of inflammatory cells into the synovium was remarkably inhibited by combination therapy and
importantly, no bone erosion and joint destructions were observed in combination therapy group. In addition, combined
administration of these two DMARDs suppressed production of cytokines (IL-17, IFN-γ, IL-6 and TNF-α) and antibodies
(IgG and IgG2b) in serum, as well as humoral and cellular responses in CIA mice. Consistent with its effects in vivo,
iguratimod combined with methotrexate significantly suppressed T and B cells responses in vitro. Taken together, our
findings suggest that combination treatment with iguratimod and methotrexate should be an intriguing and preferable
therapeutic strategy for treating RA.